# The Effect Of Fractional CO2 Laser Therapy On Cancer Survivors With Genitourinary Syndrome Of Menopause (GSM)

> **NCT06318052** · NA · UNKNOWN · sponsor: **Lumenis Be Ltd.** · enrollment: 68 (estimated)

## Conditions studied

- Vaginal Atrophy Patients With GSM

## Interventions

- **DEVICE:** The FemTouch delivery system
- **DRUG:** Gynomunal gel treatment

## Key facts

- **NCT ID:** NCT06318052
- **Lead sponsor:** Lumenis Be Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2024-11
- **Final completion:** 2024-11
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2024-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06318052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06318052, "The Effect Of Fractional CO2 Laser Therapy On Cancer Survivors With Genitourinary Syndrome Of Menopause (GSM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06318052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*